157 results on '"Sahastrabuddhe, Sushant"'
Search Results
2. Chikungunya vaccine development, challenges, and pathway toward public health impact
3. Vaccine value profile for Chikungunya
4. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study
5. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
6. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infants
7. A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age
8. Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose
9. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
10. Biases in COVID-19 vaccine effectiveness studies using cohort design.
11. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study
12. One-month follow up of a randomized clinical trial-phase II study in 6 to
13. Spectroscopic characterisation of a series of Salmonella Typhi Vi-diphtheria toxoid glycoconjugate antigens differing in polysaccharide-protein ratio
14. Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers
15. Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis.
16. Vaccine value profile for Chikungunya
17. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
18. Programmatic considerations for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: stakeholder analysis
19. The Selangor Consensus: strengthening clinical trials for local public health in the Western Pacific
20. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
21. Unpacking the vaccine clinical trial ecosystem: implementing adaptive design, leveraging pandemic experience, & supporting resource-limited settings
22. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report
23. Safety and Protective Effects of Influenza Vaccination in Pregnant Women on Pregnancy and Birth Outcomes in Pune, India: A Cross-Sectional Study
24. Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method
25. Status of paratyphoid fever vaccine research and development
26. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trial
27. Chikungunya Seroprevalence, Force of Infection, and Prevalence of Chronic Disability in Endemic and Epidemic Settings: Systematic Review, Meta-Analysis, and Modelling Study
28. Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan
29. The Need for an Information Communication and Advocacy Strategy to Guide a Research Agenda to Address Burden of Invasive Nontyphoidal Salmonella Infections in Africa
30. Typhoid Fever Surveillance and Vaccine Use — South-East Asia and Western Pacific Regions, 2009–2013
31. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus
32. Factors affecting willingness to participate in vaccine clinical trials in an underdeveloped country: perspective from Nepal
33. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
34. Typhoid Fever Vaccines
35. Typhoid Fever Vaccines
36. Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
37. Epidemiology of Typhoid in Nepal: Review of Literature to Identify High Burden Area for Potential Use of Typhoid Vaccine
38. Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development
39. Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead
40. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report
41. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)
42. Mapping the high burden areas of cholera in Nepal for potential use of oral cholera vaccine: An analysis of data from publications and routine surveillance systems
43. Spatial and Temporal Patterns of Typhoid and Paratyphoid Fever Outbreaks: A Worldwide Review, 1990–2018
44. Overview of the Typhoid Conjugate Vaccine Pipeline: Current Status and Future Plans
45. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine
46. Barriers to typhoid fever vaccine access in endemic countries
47. The Euvichol story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships
48. The Need for an Information Communication and Advocacy Strategy to Guide a Research Agenda to Address Burden of Invasive NontyphoidalSalmonellaInfections in Africa
49. 25 Years after Vi Typhoid Vaccine Efficacy Study, Typhoid Affects Significant Number of Population in Nepal
50. Increasing rates ofSalmonellaParatyphi A and the current status of its vaccine development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.